Tiziana Life Sciences (NASDAQ:TLSA) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tiziana Life Sciences (NASDAQ:TLSA) from a sell rating to a strong sell rating in a research report report published on Saturday,Wall Street Zen reports.

Several other brokerages have also recently commented on TLSA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tiziana Life Sciences in a report on Wednesday, August 26th. BTIG Research restated a “buy” rating on shares of Tiziana Life Sciences in a report on Tuesday, September 22nd. Finally, Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tiziana Life Sciences has a consensus rating of “Hold”.

Tiziana Life Sciences Trading Down 4.5%

NASDAQ:TLSA opened at $1.07 on Friday. The stock has a fifty day simple moving average of $1.01 and a 200 day simple moving average of $1.17. Tiziana Life Sciences has a 1-year low of $0.76 and a 1-year high of $2.33.

Insider Transactions at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi acquired 237,616 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the transaction, the chief executive officer owned 4,793,684 shares of the company’s stock, valued at $4,793,684. The trade was a 5.22% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders bought 988,423 shares of company stock valued at $985,909. 39.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC lifted its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 12.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,900 shares of the company’s stock after purchasing an additional 12,000 shares during the quarter. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company’s research centers on treatments designed to modulate immune responses without broadly suppressing immune function.

Tiziana’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.